巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Omeros Corp

OMER
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Omeros Corp - 延遲價格・最後更新於 26/01 12:15
最高位
5.745
最低位
5.290
開市價
--
前收市價
5.395
成交量(千)
80.62
成交額(百萬)
3.71
買入
--
賣出
--
每手股數
--
市值(百萬)
333.35
市盈率
--
息率
--
差價
--
52週高低
23.850 - 4.843
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Omeros Corp
證券代碼
OMER.US
所屬板塊
Biotechnology
公司業務
Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
發行量
61933806
公司總部
201 Elliott Avenue West
公司網址
https://www.omeros.com
公司電話
+1 206 676-5000
暫無內容

關於

Omeros Corp(OMER.US)所屬的行業板塊為Biotechnology。
Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
詳細公司背景可參考: https://www.omeros.com